Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

444.77 +3.47 (+0.79%)
Streaming Delayed Price Updated: 12:34 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
Vertex: Strong Sales, Stronger Pipeline
Via The Motley Fool
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller. 
Via Stocktwits
Markets Steady, Positive; Q4 Earnings Keep Rolling
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline... 
Via Talk Markets
Topics Government Stocks / Equities World Trade
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Vertex Pharmaceuticals Unusual Options Activity
Via Benzinga
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share. 
Via The Motley Fool
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the... 
Via StockStory
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth potential. Stock has bullish technicals but risks remain. 
Via Benzinga
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
Via Benzinga
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports. 
Via Benzinga
Topics World Trade
McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday
Stock futures up, focus on McDonald's, ON Semiconductor, VOXX, Rockwell Automation, Vertex Pharmaceuticals. 
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in February
Via The Motley Fool
Earnings Scheduled For February 10, 2025
Via Benzinga
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. 
Via StockStory
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades'
UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72. 
Via Benzinga
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Via The Motley Fool
3 Magnificent Stocks to Buy and Hold Forever
Via The Motley Fool
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Via The Motley Fool
What You Missed On Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Topics Stocks / Equities
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Via The Motley Fool
Small- To Mid-Cap Biotech Trades Poised For Gains
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options. 
Via Benzinga
Topics Cannabis
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
Top S&P500 movers in Friday's session
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Vertex Pharmaceuticals Stock Soars As Non-Opioid Pain Treatment Gets FDA Nod
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain. 
Via Talk Markets
Topics Stocks / Equities
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter
The company won Food and Drug Administration approval for its non-opioid painkiller pill on Thursday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.